Q-omics provides the consensus-scored MIR361 profile across patient tissues and cancer cell-line models. MIR361 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MIR361 is differentially expressed in 3, with the highest sampling consensus in READ. Additionally, MIR361 RNA expression shows 10,302 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, READ, and THYM as cancer lineages where MIR361 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR361 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR361 survival associations across molecular data types. MIR361 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR361 RNA expression–survival associations across cancer types. High MIR361 expression shows unfavorable associations in MESO, HNSC, DLBC, LIHC and CESC, but favorable associations in COAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .032). Together, the overview and detailed table identify MESO as the clearest survival context for MIR361 RNA expression.
This table summarizes MIR361 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in READ for RNA.
This table ranks reproducible tumor–normal expression differences for MIR361. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR361 shows lower tumor expression in LUSC and higher tumor expression in READ and HNSC. The READ box plot shows higher MIR361 RNA expression in tumor versus normal tissue (log2 FC = +0.660, t-test p < 0.001).
This table shows molecular features associated with MIR361 in patient tissues and cancer cell lines. In patient samples, MIR361 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
